Nordion, Inc. has entered into an agreement to divest its Targeted Therapies business to BTG plc, a specialist healthcare company based in London, for $200 million in cash. The transaction is expected to close by the end of June 2013.   BTG will acquire TheraSphere, a targeted liver cancer therapy, and Nordion has agreed to continue manufacturing TheraSphere under a Manufacturing and Support Agreement for three years, plus a two-year extension at BTG’s option. Approximately 40 Nordion employees ...